Tuesday, April 19, 2016

Investigating plasma levels as a biomarker for Alzheimer's disease

Investigating plasma levels as a biomarker for Alzheimer's disease:

Dementia Big
A Centre for Healthy Brain Ageing (CHeBA) paper published in Current Alzheimer Research presents the first detailed study of the relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics (measures studying the size of brain, which shrinks with Alzheimer’s disease) and cognitive performance in an investigation of the usefulness of plasma levels as a biomarker for Alzheimer’s disease (AD).


http://ift.tt/1SrQmUR

No comments:

Post a Comment